SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03862885

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

This is a US, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.

NCT03862885 GIST
MeSH: Gastrointestinal Stromal Tumors
HPO: Gastrointestinal stroma tumor

1 Interventions

Name: Avapritinib

Description: Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles.

Type: Drug



There is one SNP

SNPs


1 D842V

4. Patient has received 3 or more TKI therapies including imatinib, or the patient has GIST that carries a mutation in exon 18 of the PDGFRA gene (such as D842V). 5. --- D842V ---



HPO Nodes


HPO:
Gastrointestinal stroma tumor
Genes 17
CD19 MS4A1 TNFRSF13C CR2 PDGFRA TNFSF12 KIT TNFRSF13B PRKCD CD81 SDHA NFKB1 SDHB NFKB2 SDHC SDHD ICOS